Under Armour Inc Class A vs Zoetis Inc — how do they compare? Under Armour Inc Class A trades at $7.18 (market cap $3.07B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 10.4× Under Armour Inc Class A's market cap, and Zoetis Inc pays a 2.78% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| UA | ZTS | |
|---|---|---|
Market Cap | $3.07B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $156.76 |
52-Week Low | $3.96 | $71.91 |
Enterprise Value | $4.70B | $39.24B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $201.27 million for 2025, with revenue of $5.16 billion, and faces declining revenue projections for 2026. Recent news includes a Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
The outlook remains challenged by negative profitability and cash flow, though analyst consensus leans slightly bullish with 40.3% buy ratings. Key risks include sustained revenue declines and high debt, while potential upside hinges on successful execution of premium product focus and inventory management strategies.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →